Drew Ranieri
Stock Analyst at Morgan Stanley
(1.22)
# 3,661
Out of 5,063 analysts
168
Total ratings
44.44%
Success rate
-11.86%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $19.61 | +7.09% | 11 | Nov 10, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $82.28 | -17.36% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $5.12 | +17.19% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $360.48 | +23.45% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $18.68 | +1.71% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $11.05 | +144.34% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.61 | +206.51% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $21.16 | +3.97% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $13.49 | -40.71% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $4.44 | +1,758.11% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $19.11 | +98.85% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $75.12 | +27.80% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $10.89 | +138.75% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $189.58 | +55.61% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $104.64 | +167.58% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.53 | -23.43% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $17.42 | +301.84% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $552.23 | -45.67% | 6 | Apr 25, 2022 |
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $19.61
Upside: +7.09%
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $82.28
Upside: -17.36%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $5.12
Upside: +17.19%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $360.48
Upside: +23.45%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $18.68
Upside: +1.71%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $11.05
Upside: +144.34%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.61
Upside: +206.51%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $21.16
Upside: +3.97%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $13.49
Upside: -40.71%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $4.44
Upside: +1,758.11%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $19.11
Upside: +98.85%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $75.12
Upside: +27.80%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $10.89
Upside: +138.75%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $189.58
Upside: +55.61%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $104.64
Upside: +167.58%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.53
Upside: -23.43%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $17.42
Upside: +301.84%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $552.23
Upside: -45.67%